The advent of molecularly targeted anticancer therapy could cause a certain lack of interest in the development of novel conventional cytotoxic drugs. However, molecularly targeted agents have not shown any curative properties when administered as monotherapy. The current article focuses on one such anticancer drug that is used in treating colorectal cancers. Colorectal cancer is the third most common primary malignancy and is the second cause of cancer-related deaths.
The backbone of treatment for localized disease is surgical resection followed by adjuvant chemotherapy for 6 months in stage III tumors, as chemotherapy improves cure rate. In that regard, there is hope in combining molecularly targeted anticancer therapy with conventional cytotoxic chemotherapy. Such combinations can come about only through rational design of clinical trials, taking into account the pharmacology and…
